• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    1/15/24 8:05:45 AM ET
    $AHG
    $ATNF
    $ENSC
    $EVOK
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 19.2% to $93.0 during Monday's pre-market session. The company's market cap stands at $720.7 million.
    • Akso Health Group (NASDAQ:AHG) stock moved upwards by 17.97% to $1.05. The market value of their outstanding shares is at $24.0 million.
    • CytoMed Therapeutics (NASDAQ:GDTC) stock increased by 14.78% to $4.97. The market value of their outstanding shares is at $57.3 million.
    • Regional Health Props (AMEX:RHE) stock rose 12.56% to $2.33. The market value of their outstanding shares is at $4.3 million.
    • Ocean Biomedical (NASDAQ:OCEA) stock increased by 12.4% to $0.7. The market value of their outstanding shares is at $23.9 million.
    • cbdMD (AMEX:YCBD) stock moved upwards by 11.2% to $0.89. The market value of their outstanding shares is at $2.6 million.

    Losers

    • MAIA Biotechnology (AMEX:MAIA) shares declined by 19.1% to $1.14 during Monday's pre-market session. The market value of their outstanding shares is at $19.3 million.
    • NewAmsterdam Pharma (NASDAQ:NAMS) stock fell 18.18% to $14.0. The company's market cap stands at $1.1 billion.
    • Evoke Pharma (NASDAQ:EVOK) shares fell 10.6% to $0.76. The market value of their outstanding shares is at $2.5 million.
    • Grifols (NASDAQ:GRFS) shares fell 8.92% to $7.25. The company's market cap stands at $4.9 billion.
    • 180 Life Sciences (NASDAQ:ATNF) shares declined by 8.48% to $0.21. The company's market cap stands at $2.0 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares fell 7.81% to $1.3. The company's market cap stands at $4.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $ATNF
    $ENSC
    $EVOK

    CompanyDatePrice TargetRatingAnalyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    10/20/2025$52.00Buy
    H.C. Wainwright
    NewAmsterdam Pharma Company N.V.
    $NAMS
    8/25/2025$45.00Overweight
    Wells Fargo
    NewAmsterdam Pharma Company N.V.
    $NAMS
    7/17/2025$27.00Neutral
    Goldman
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/17/2025$42.00Buy
    Citigroup
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/10/2025$44.00Buy
    Stifel
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    NewAmsterdam Pharma Company N.V.
    $NAMS
    12/30/2024$48.00Buy
    H.C. Wainwright
    More analyst ratings

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

    New York, March 05, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology March 2026 Update Note Highlights from the note include:                                               $30 Million Equit

    3/5/26 4:00:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

    Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 3,000,0

    3/4/26 4:00:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

    Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common s

    3/2/26 10:45:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    3/10/26 8:58:01 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 300,000 units of Ordinary Shares and sold $9,090,868 worth of Ordinary Shares (300,000 units at $30.30) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    3/9/26 8:18:01 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Davidson Michael H. converted options into 443,707 units of Ordinary Shares and sold $14,753,258 worth of Ordinary Shares (443,707 units at $33.25) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    3/2/26 6:08:05 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AHG
    $ATNF
    $ENSC
    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AHG
    $ATNF
    $ENSC
    $EVOK
    SEC Filings

    View All

    H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target

    H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00

    10/20/25 8:45:44 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on NewAmsterdam Pharma with a new price target

    Wells Fargo initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $45.00

    8/25/25 8:22:07 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on NewAmsterdam Pharma with a new price target

    Goldman initiated coverage of NewAmsterdam Pharma with a rating of Neutral and set a new price target of $27.00

    7/17/25 8:08:01 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

    144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    3/6/26 5:52:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by cbdMD Inc.

    EFFECT - cbdMD, Inc. (0001644903) (Filer)

    3/5/26 12:15:15 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 424B4 filed by cbdMD Inc.

    424B4 - cbdMD, Inc. (0001644903) (Filer)

    3/4/26 5:24:35 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Financials

    Live finance-specific insights

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AHG
    $ATNF
    $ENSC
    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care